Management of psoriatic disease with anti IL-17 and anti-IL-23 monoclonal antibodies

Abstract

Mechanismus of therapeutic activity of interleukin 17 a 23 inhibition (anti-IL-17 and anti-IL-23) in moderate to severe forms of psoriatic diseases are reviewed, including classification accoding to mechanismus of action as well as description of different molecules inhibiting these key regulating and effector cytokines.

Keywords

• psoriatic diseases
• anti-IL-17management
• anti-IL-23 management